QURE
uniQure N.V. (QURE)
Healthcare • NASDAQ • $27.66+14.53%
- Symbol
- QURE
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $27.66
- Daily Change
- +14.53%
- Market Cap
- $1.74B
- Trailing P/E
- N/A
- Forward P/E
- -8.03
- 52W High
- $71.50
- 52W Low
- $8.73
- Analyst Target
- $39.60
- Dividend Yield
- N/A
- Beta
- 0.87
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement wi…
Company websiteResearch QURE on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.